of CLL patients. 8, 9 Furthermore, the monoclonal B-lymphocytosis precursor state, which precedes the clinically relevant leukemic phase in virtually all CLL patients, sometimes involves multiple B-cell clones. 10 It is still unknown whether two or more CLL clonotypes within the same patient potentially associate with the same antigenic reactivity, or alternatively arise as stochastic and antigenindependent events, fostered by the accumulation of oncogenic abnormalities in the preleukemic state. To answer this question, here we have characterized the epitope recognition profiles of CLL clonotypes by coupling the genetic analysis of Ig variable genes and the epitopic reactivity at single-cell level.
We isolated single CD5 + B cells from peripheral blood of six newly diagnosed untreated CLL patients, randomly referred to the Medical Oncology Unit-University Magna Graecia of Catanzaro. CLL patients displayed the typical CLL immunophenotype, with no evidence of separate/aberrant B-cell populations (Supplementary  Table S1 ). We determined the V H DJ H and V L J L complementary DNA (cDNA) sequence of at least 20 single leukemic cells per patient (Supplementary Table S2 ). All cDNA sequences showed a productive rearrangement at the heavy-and light-gene loci. In particular, we detected single and distinct V H DJ H and V L D L rearrangements in CLL#1, CLL#2 and CLL#3, indicating the presence of a single clonotype (Table 1, Supplementary Table  S2) . Differently, CLL#4, CLL#5 and CLL#6 exhibited two different V H DJ H rearrangements, each of them pairing with a unique and Figure S1) . Of note, the Vκ usage of clonotypes CLL5-1, CLL6-1 and CLL6-2 were univocally assigned to Vκ genes of the distal cluster, which is evocative of receptor editing.
The analysis of nucleotide differences among the V H sequences of the same clonotype showed a variable degree of base-pair substitutions (Supplementary Table S3 ). Despite the intraclonal diversity of the V H region, each clonotype showed either an identical or two quasi-identical V H CDR3 amino acid sequences (Table 1 and Supplementary Table S3 ). By comparing the V H CDR3 amino acid sequence of clonotypes with a data set of stereotypic Ig-BCRs, 5 CLL6-2 was found to be a member of the major subset 16, whereas other clonotypes did not fall within the stereotypic subsets (Table 1) .
Next, we aimed to identify peptide mimetics of the natural epitope (hereafter, referred as mimotopes) that bound to the Ig-BCR of CLL clonotypes. To this end, we produced monoclonal antibodies IgG1 (mIgCLLs) that carried the V H DJ H and V L J L rearrangements of CLL clonotypes linked to an IgHCγ1, or IgLCκ/λ segment, as described 11 ( Table 1 , Supplementary Figure S2 ). The ) from CLL#1 patient (left panel) were incubated with N-biotinylated pCLL1 mimotope (10 pM), stained with strepavidin-FITC (1:100), anti-human-IgM PE (1:100), anti-CD5-APC (1:100) and analyzed by confocal microscopy. Scale bar: 5 μm. (c) Enzyme-linked immunosorbent assay (ELISA)-binding reactivity of selected mimotopes against the mIgCLLs. 'pCLL' is the labeling for peptide (mimotope) ligand; 'mIgCLL' is the labeling for the recombinant, CLL-derived Ig. Relative absorbance was calculated as the difference between optical density 405 nm and optical density 620 nm divided by the absorbance of the blank sample, and reported as shades of green at the bottom. The white square indicates ELISA absorbance value less than twofold relative to blank, indicating no interaction in ELISA.
mIgCLLs were used as baits for screening a constrained (CX7C) random phage-displayed peptide library, 12 which resulted in the isolation of at least 25 phage clones for each mIgCLL bait (Supplementary Table S4 ). We observed a considerable difference of enzyme-linked immunosorbent assay (ELISA)-binding reactivity among the phage clones isolated through the same mIgCLL (Supplementary Figure S3) . As mimotopes are equally distributed among phage particle (five copies per phage), we assumed that the differences in the binding affinity of distinct mimotopes to the same mIgCLL might account for the differences in the ELISAbinding reactivity.
Hence, we synthesized a number of peptides corresponding to the phage-displayed mimotopes that had shown the highest binding affinity toward the cognate mIgCLL (Table 1) . Synthetic mimotopes bound in a dose-dependent manner to the cognate mIgCLL, whereas tested negative for control human polyclonal Igs (Supplementary Figure S4) , demonstrating that the selected mimotopes maintained the mIgCLL-binding ability out of the phage context. The equilibrium constant K D of synthetic mimotope binding to the cognate mIgCLL was in the nanomolar range, as estimated by the Scatchard plot analysis ( Table 1 ).
All mimotopes bound to the corresponding CLL cells, and not to normal B (sIg + /CD19 + ) or non-B cells (sIgG Figure S5) . Moreover, mimotopes colocalized with the sIg-BCR on the surface of the cognate B-CLLs, as shown by the confocal microscopy ( Figure 1b) . Overall, these data confirmed that the mimotope binding to the corresponding B-CLL cells was specifically achieved through direct interaction with the sIg-BCR, thus validating the selected mimotopes as truly representative of the epitopic reactivity of the original CLL cells.
Then, we performed a systematic characterization of the epitopic reactivity of CLL clonotypes by probing the binding of individual mIgCLLs to all selected mimotopes by ELISA. Each mIgCLL was able to bind not only to its cognate mimotope, but also to distinct mimotopes of others mIgCLLs (Figure 1c) . These results highlighted a certain degree of common epitopic reactivity among the mIgCLLs, as previously reported by others. 13, 14 A first level of common reactivity regarded the mIgCLLs derived from the same patient that invariably shared the epitopic reactivity, regardless they were classified as distinct clonotypes. In particular, the mIgCLLs with quasi-identical V H CDR3, which were derived from patients harboring a unique clonotype (mIgCLL2-1 and mIgCLL2-2 from patient CLL#2; mIgCLL3-1 and mIgCLL3-2 from patient CLL#3), equally bound to the two selected mimotopes (pCLL2-1 and pCLL2-2 for patient CLL#2; pCLL3-1 and pCLL3-2 for patient CLL#3), thus indicating that the small differences in their V H CDR3 did not affect their binding affinity (Figure 1c ). The mIgCLLs derived from patients harboring two different clonotypes (mIgCLL4-1 and mIgCLL4-2; mIgCLL5-1 and mIgCLL5-2; mIgCLL6-1 and mIgCLL6-2) also showed common epitopic reactivity, even though with different ELISA reactivity. Thus, the diverse V H CDR3 pattern of distinct CLL clonotypes harbored by the same patient did not prevent the binding to a common set of mimotopes.
A second level of shared epitopic reactivity was observed for some mIgCLLs derived from different patients. In particular, the mIgCLLs derived from patients CLL#1, CLL#2 and CLL#6 recognized the same subset of mimotopes (pCLL1, pCLL2-1, pCLL2-2, pCLL6-1 and pCLL6-2; Figure 1c) . The mIgCLL4-2 also shared a similar ELISA-binding profile, except for the binding to pCLL1-2.
The clonotypic mIgCLL1, mIgCLL2, mIgCLL4-2, mIgCLL6-1 and mIgCLL6-2 did not show any obvious similarity in the V H CDR3 primary structure, or a preferential usage of V H and V L regions that would account for the common binding to the same subset of mimotopes. Hence, their shared epitopic reactivity should lie on structural motifs of the whole V H and V L regions, which will require further investigation.
Overall, these data demonstrated that (a) mIgCLLs derived from independent B-cell clones of the same CLL patient shared the epitopic reactivity and (b) a subset of CLLs exhibited some degree of common epitope reactivity.
Our results confirmed recent findings on the appearance of two or more independent B-CLL clones within the same patient. [8] [9] [10] Importantly, we document for the first time that the Ig-BCRs of unrelated clonotypes in the same CLL patient may recognize common epitopes, thus revealing a striking homogeneity, grounded on epitopic reactivity, that was unpredictable from the molecular features of the Ig-BCR, including the CDR3 composition and length. The coexistence within the same patient of two unrelated CLLs clonotypes associated with the same epitopic reactivity reinforces the key role of antigenic selection in CLL pathogenesis and demand a more exhaustive understanding of the biology of this disease based on epitopic reactivity. The diagnosis of myelodysplastic syndrome (MDS) requires persistent cytopenias, not otherwise explained, and evidence of morphologic dysplasia in the bone marrow. Low-grade MDS (bone marrow blasts o 5%) has morphologic dysplasia in at least 10% of cells in one or more cell lineages.
1 Low-grade MDS is particularly challenging to diagnose, as no definitive criteria for morphologic dysplasia exist and evaluation may be subject to high interobserver variability. [1] [2] [3] The ability to diagnose low-grade MDS can be improved by incorporating cytogenetic evaluation of the bone marrow, especially in the setting of equivocal morphologic dysplasia. However, many MDS cases (up to 60%) lack cytogenetic abnormalities, limiting the overall utility of cytogenetics as a diagnostic adjunct. 4 Multiple studies have demonstrated that the majority of MDS patients (~80% in some studies) harbor recurrent somatic mutations in a group of 20-30 genes. [5] [6] [7] Further, some gene mutations confer an adverse prognosis independent of clinical scoring systems. 5, 6, 8 We sought to determine whether targeted DNA sequencing of recurrently mutated MDS genes could be a useful adjunct in the diagnostically challenging subgroup of cytopenic patients with low blast counts and a normal karyotype, thereby identifying a subset of patients that may potentially be at a higher risk of developing MDS or acute myeloid leukemia (AML).
We screened 599 patients who presented between 1/2002 and 11/2015, consented for sequencing studies on a protocol approved by the Human Research Protection Office at Washington University, and had banked bone marrow and control tissue (skin). Forty-three patients were selected based on (1) stringent cytopenia criteria (WBC o1800/μl, hemoglobin o10 g/dl, platelets o100k/μl) in at least one lineage, (2) bone marrow blasts o 5% by flow cytometry and/or morphologic evaluation (and had slides available for review), (3) WBC o14k/μl, (4) nonclonal metaphase cytogenetics, and (5) absence of prior therapy for MDS (Table 1) . Bone marrow specimens were independently reviewed (blinded) for blast count and dysplasia by two boardcertified hematopathologists (EJD and KV) and the percentage of dysplastic cells in the myeloid, erythroid and megakaryocytic lineages enumerated. Dysplasia was binned into categories of o 10, 10-20, 21-50 and 450%. Definitive dysplasia was established when both pathologists identified dysplasia in ⩾ 10% of cells in at least one lineage. Equivocal dysplasia was rendered when there was disagreement over the identification of ⩾ 10% dysplasia in at least one lineage. No dysplasia was rendered when both pathologists agreed that dysplasia was o 10% in all lineages. Genomic DNA was extracted from bone marrow and skin (as a source of normal DNA) and enriched for the coding exons of a panel of 284 commonly mutated myeloid genes (Supplementary Table 1) . [5] [6] [7] [8] DNA was extracted from aspirate coverslips for followup cases when cryopreserved cells were not available. Libraries were sequenced on a HiSeq 2500 (Illumina, San Diego, CA, USA) instrument with 2 × 101 bp reads. The resulting data was analyzed for single nucleotide variants (SNVs) and insertions/deletions (indels), using standard analysis pipelines in paired normal mode, as previously reported. 9 To reduce false positive calls, only variants with ⩾ 5 variant reads, ⩾ 50 × total coverage in marrow and skin samples, ⩾ 5% variant allele fraction (VAF, variant reads/total reads) in the marrow, not present in the database of short genetic variations (unless known canonical somatic hotspot mutations), and that resulted in protein coding changes were conservatively included in the analysis. Copy number alterations and loss-ofheterozygosity were called using the CopyCAT2 package.
Mean unique coverage depth was 265 × for primary bone marrows, 252 × for skin, and 388 × for follow-up coverslips. Of the 43 sequenced cases, 29 had a coding-region somatic mutation in at least one gene (mean 2.8 mutations/case, range 1-8 mutations/ case). The most commonly mutated gene was SRSF2 (8 cases), followed by TET2 (7 cases), SF3B1 (6 cases) and U2AF1 (6 cases) (Figure 1a ). Of the 284 sequenced genes, 40 were mutated in at Accepted article preview online 30 August 2016; advance online publication, 30 September 2016
